CompuGroup Medical SE & Co. KGaA and investor CVC Capital Partners have announced a public delisting acquisition offer for the shares of CompuGroup Medical. This offer is highly relevant for investors, as it will have significant implications for the company’s future trading opportunities and market positioning.
Background and Details of the Offer
- Offer and Price: CVC has proposed a public delisting acquisition offer of €22.00 per share in cash. This gives shareholders the opportunity to sell their shares before the delisting, regardless of market conditions.
- CVC’s Shareholding: CVC currently holds 24.27% of the share capital of CompuGroup Medical.
- Support from Management: The delisting is supported by the management team, including the executive board and the supervisory board. They believe that the delisting will promote the company’s long-term growth and innovation strategies.
Involvement of the Gotthardt Family
- Gotthardt Family Shareholding: The Gotthardt family, holding 50.12% of the share capital, will not sell their shares. Together with CVC, they form a strong partnership that drives this initiative forward.
- Executives: Frank Gotthardt remains chairman of the supervisory board, while Prof. (apl.) Dr. med. Daniel Gotthardt continues as CEO and member of the supervisory board.
Objectives and Impacts
- Future Strategy: The delisting aims to enable CompuGroup Medical to focus more on developing healthcare software and to grow in the long term. The partnership with CVC is expected to strengthen innovation in the healthcare sector.
- Market Positioning: Through the delisting, CompuGroup Medical will no longer be traded on the stock exchange, which may increase the company’s flexibility to make strategic decisions without public scrutiny and associated requirements.
Timeline
- Publication of the Offer: The delisting offer is expected to be published in May 2025, with the goal of completing the process in the first half of the fiscal year.
Overall, the delisting aims to empower CompuGroup Medical to concentrate on its core competencies in healthcare software and strengthen its competitiveness while receiving support from CVC and the Gotthardt family.